Galidesivir

Source: Wikipedia, the free encyclopedia.
Galidesivir
Legal status
Legal status
Identifiers
  • (2S,3S,4R,5R)-2-(4-Amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
JSmol)
  • O[C@H]3[C@H](c2c1ncnc(N)c1[nH]c2)N[C@H](CO)[C@H]3O
  • InChI=1S/C11H15N5O3/c12-11-8-6(14-3-15-11)4(1-13-8)7-10(19)9(18)5(2-17)16-7/h1,3,5,7,9-10,13,16-19H,2H2,(H2,12,14,15)/t5-,7+,9-,10+/m1/s1
  • Key:AMFDITJFBUXZQN-KUBHLMPHSA-N

Galidesivir (BCX4430, immucillin-A) is an

Ebola virus disease and Marburg virus disease, as well as Zika virus.[3] Currently, galidesivir is under phase 1 human trial in Brazil for coronavirus.[4]

It also shows

Galidesivir later showed efficacy against Zika virus in a mouse model.[7]

Galidesivir abrogates viremia in Zika virus–infected rhesus Macaques.[8]

Galidesivir is one of several antiviral drugs being tested for

coronavirus disease 2019.[9]

On April 9, 2020, BioCryst opened enrollment into a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19.[4]

See also

References

  1. ^
    PMID 24590073
    .
  2. .
  3. ^ BioCryst Pharmaceuticals, Inc. (June 10, 2020). "Galidesivir Stops Zika Viral Replication in Primate Model". GlobeNewswire News Room (Press release).
  4. ^ a b Clinical trial number NCT03891420 for "A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19" at ClinicalTrials.gov
  5. PMID 29864447
    .
  6. ^ Rodgers P (8 April 2014). "BioWar Lab Helping To Develop Treatment For Ebola". Forbes Magazine.
  7. PMID 27838352
    .
  8. .
  9. ^ Duddu P (19 February 2020). "Coronavirus outbreak: Vaccines/drugs in the pipeline for Covid-19". clinicaltrialsarena.com. Archived from the original on 19 February 2020. Retrieved 19 February 2020.